Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Kiniksa Pharmaceuticals, Ltd. (KNSA)  
$19.53 0.66 (3.27%) as of 4:30 Fri 5/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 35,410,000
Market Cap: 691.56(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $13.21 - $21.74
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 128,310 194,896 224,296 274,612
Total Sell Value $2,726,499 $3,969,036 $4,531,208 $5,316,305
Total People Sold 4 5 5 6
Total Sell Transactions 8 12 14 16
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 241
  Page 9 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ragosa Mark Interim CFO   •       –      –    2020-12-31 4 D $17.67 $22,918 D/D (1,297) 3,107     -
   Ragosa Mark Interim CFO   •       –      –    2020-12-31 4 OE $0.00 $0 D/D 4,404 4,404     -
   Patel Sanj K Chairman & CEO   •       •      –    2020-10-12 4 AS $21.02 $2,087,917 I/I (99,330) 112,570 10%     
   Patel Sanj K Chairman & CEO   •       •      –    2020-10-12 4 AS $21.02 $3,167,714 D/D (150,700) 0 10%     
   Patel Sanj K Chairman & CEO   •       •      –    2020-10-12 4 OE $1.59 $239,613 D/D 150,700 150,700     -
   Patel Sanj K Chairman & CEO   •       •      –    2020-10-09 4 AS $21.00 $14,070 I/I (670) 211,900 10%     
   Patel Sanj K Chairman & CEO   •       •      –    2020-10-09 4 AS $21.00 $18,312 D/D (872) 0 10%     
   Patel Sanj K Chairman & CEO   •       •      –    2020-10-09 4 OE $1.59 $1,386 D/D 872 872     -
   Beetham Thomas W. EVP & Chief Legal Officer   •       –      –    2020-07-01 4 AS $25.32 $750,678 D/D (29,589) 0 -39%     
   Megna Michael R Chief Accounting Officer   •       –      –    2020-06-30 4 A $9.51 $6,096 D/D 641 1,778     -
   Beetham Thomas W. EVP & Chief Legal Officer   •       –      –    2020-06-10 4 AS $25.07 $344,763 D/D (13,752) 29,589 -29%     
   Beetham Thomas W. EVP & Chief Legal Officer   •       –      –    2020-06-10 4 OE $1.59 $21,866 D/D 13,752 43,341     -
   Beetham Thomas W. EVP & Chief Legal Officer   •       –      –    2020-04-21 4 AS $19.56 $50,092 D/D (2,518) 29,589 -14%     
   Beetham Thomas W. EVP & Chief Legal Officer   •       –      –    2020-04-20 4 AS $19.06 $903,882 D/D (47,423) 32,107 -13%     
   Patel Sanj K Chairman & CEO   •       •      –    2020-03-06 4 AS $20.00 $662,300 I/I (33,115) 212,570 13%     
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-27 4 OE $1.86 $22,320 D/D 12,000 30,000     -
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-20 4 AS $18.91 $185,832 D/D (9,803) 18,000 36%     
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-20 4 OE $3.80 $37,251 D/D 9,803 27,803     -
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-19 4 AS $18.27 $410,655 D/D (22,477) 18,000 42%     
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-19 4 OE $3.80 $85,413 D/D 22,477 40,477     -
   Beetham Thomas W. EVP & Chief Legal Officer   •       –      –    2020-02-14 4 AS $18.58 $1,096 D/D (59) 79,530 40%     
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-14 4 AS $18.33 $19,045 D/D (1,039) 18,000 40%     
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-14 4 OE $3.80 $3,948 D/D 1,039 19,039     -
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-13 4 AS $18.29 $187,966 D/D (10,277) 18,000 37%     
   Paolini John F. SVP & Chief Medical Officer   •       –      –    2020-02-13 4 OE $3.80 $39,053 D/D 10,277 28,277     -
  241 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 9 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us